Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 1Muscle Invasive Bladder Carcinoma 1Muscle Invasive Bladder Cancer 1HER2 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

Fluorouracil 80Oxaliplatin 72Leucovorin 66Irinotecan 60Capecitabine 58Bevacizumab 57Cetuximab 43Folfox protocol 22Drug Therapy 22Neoadjuvant Therapy 19HMPL-013 17Colonoscopy 17regorafenib 15apatinib 11Panitumumab 11Chemotherapy, Adjuvant 11trifluridine tipiracil drug combination 10XELOX 10Laparoscopy 10IFL protocol 10sintilimab 9raltitrexed 9Radiotherapy 9Blood Specimen Collection 9Surveys and Questionnaires 8Surgical Procedures, Operative 8tislelizumab 7pembrolizumab 7Endoscopic Mucosal Resection 7Aspirin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Colorectal Neoplasms × disitamab vedotin × Clear all
NCT05578287 2023-12-07

DETECT

Sun Yat-sen University

Phase 2 Unknown
29 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05493683 2022-10-21

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
29 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05333809 2022-04-20

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Shanghai Zhongshan Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡